📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Apollomics

1.1 - Company Overview

Apollomics Logo

Apollomics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of oncology biopharmaceuticals discovering and developing mono- and combination therapies to harness the immune system. Pipeline: APL-502 (PD-L1 mAb) and APL-501 (PD-1 mAb) outside mainland China; EO1001/APL-122 (small molecule) for development outside mainland China, Hong Kong and Taiwan; uproleselan/APL-106 and GMI-1687/APL-108 (E-selectin antagonists) in mainland China, Hong Kong, Macau and Taiwan; TYG100/APL-810 in Greater China and South Africa.

Products and services

  • APL-501: Monoclonal antibody targeting PD-1, engineered for oncology applications outside mainland China, aligning with Apollomics’ discovery of mono- and combination oncology therapies to harness the immune system
  • APL-502: Monoclonal antibody targeting PD-L1, engineered for oncology applications outside mainland China, fitting Apollomics’ mono- and combination therapy development aimed at harnessing the immune system in cancer
  • Uproleselan (APL-106): Small molecule E-selectin antagonist licensed for development in mainland China, Hong Kong, Macau, and Taiwan, for oncology programs consistent with Apollomics’ immune-focused therapeutics

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Apollomics

Exousia Pro Logo

Exousia Pro

HQ: United States Website
  • Description: Provider of exosome-based therapeutics for cancer and other diseases, with research in plant-derived exosomes and integration of AI to support development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Exousia Pro company profile →
MediWise Logo

MediWise

HQ: United Kingdom Website
  • Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MediWise company profile →
Genoptix Logo

Genoptix

HQ: United States Website
  • Description: Provider of specialized oncology diagnostics services, regularly participating in industry conferences to share findings, discuss emerging solutions, and create connections that advance the oncology community.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genoptix company profile →
Silverback Therapeutics Logo

Silverback Therapeutics

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies, developing ImmunoTAC treatments targeting previously inaccessible disease pathways, and a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Silverback Therapeutics company profile →
Imvax Logo

Imvax

HQ: United States Website
  • Description: Provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Imvax company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Apollomics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Apollomics

2.2 - Growth funds investing in similar companies to Apollomics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Apollomics

4.2 - Public trading comparable groups for Apollomics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Apollomics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Apollomics

What does Apollomics do?

Apollomics is a provider of oncology biopharmaceuticals discovering and developing mono- and combination therapies to harness the immune system. Pipeline: APL-502 (PD-L1 mAb) and APL-501 (PD-1 mAb) outside mainland China; EO1001/APL-122 (small molecule) for development outside mainland China, Hong Kong and Taiwan; uproleselan/APL-106 and GMI-1687/APL-108 (E-selectin antagonists) in mainland China, Hong Kong, Macau and Taiwan; TYG100/APL-810 in Greater China and South Africa.

Who are Apollomics's competitors?

Apollomics's competitors and similar companies include Exousia Pro, MediWise, Genoptix, Silverback Therapeutics, and Imvax.

Where is Apollomics headquartered?

Apollomics is headquartered in United States.

How many employees does Apollomics have?

Apollomics has 1,000 employees 🔒.

When was Apollomics founded?

Apollomics was founded in 2010 🔒.

What sector and industry vertical is Apollomics in?

Apollomics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Apollomics

Who are the top strategic acquirers in Apollomics's sector and industry

Top strategic M&A buyers and acquirers in Apollomics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Apollomics?

Top strategic M&A buyers groups and sectors for Apollomics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Apollomics's sector and industry vertical

Which are the top PE firms investing in Apollomics's sector and industry vertical?

Top PE firms investing in Apollomics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Apollomics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Apollomics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Apollomics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Apollomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Apollomics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Apollomics?

The key public trading comparables and valuation benchmarks for Apollomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Apollomics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Apollomics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Apollomics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Apollomics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Apollomics's' sector and industry vertical?

Access recent funding rounds and capital raises in Apollomics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Apollomics